BioSpace News Archive

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2023, and provided an update on corporate progress.

Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2023, and provided business highlights.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported second quarter 2023 financial results and corporate highlights.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second-quarter 2023 financial results.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”).

Madrigal Pharmaceuticals, Inc. today provides a summary of recent corporate accomplishments and reports second quarter 2023 financial results.

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

IO Biotech (Nasdaq: IOBT) announced today an abstract related to the company’s Phase 2 basket trial of IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid tumors (IOB-022/KN-D38) has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid from October 20-24, 2023.

IN8bio, Inc. announced the grand opening of its advanced research and development facility in Birmingham, AL. Spanning 10,000 square feet, the state-of-the-art facility will complement IN8bio’s current GMP manufacturing spaces and bolster the Company’s preclinical, clinical, and process development capabilities to advance its groundbreaking pipeline of gamma-delta T cell therapies.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to LSTA1, the Company’s lead product candidate, for the treatment of malignant glioma.